Charles Polsky
Directeur Général chez William Harris Investors, Inc.
Profil
Charles V.
Polsky is currently the President & Chief Executive Officer at William Harris Investors, Inc. He is also the Executive Chairman at Bolden Therapeutics, Inc., a Non-executive Director at Gliknik, Inc., and a Director at WHI Special Investments LLC.
Previously, he was a Director at Tivorsan Pharmaceuticals, Inc. and the Secretary & Director at RIGImmune,.
Inc. Polsky holds a doctorate degree from The University of Chicago and an undergraduate degree from Yale University.
Postes actifs de Charles Polsky
| Sociétés | Poste | Début |
|---|---|---|
William Harris Investors, Inc.
 William Harris Investors, Inc. Investment ManagersFinance William Harris Investors, Inc. (WHI) is a privately-owned investment and wealth management firm headquartered in Chicago, Illinois. The firm serves as the family office for the Irving B. Harris family. Founded in 1976 by Irving B. Harris to manage his own family's capital, WHI has expanded its services and today provides a broad range of professional and wealth management services, including financial and estate planning, trust services, cash management, accounting and administrative services, tax preparation, and a variety of philanthropic services to four generations of the Harris family. | Directeur Général | 01/01/2002 |
WHI Special Investments LLC
 WHI Special Investments LLC Financial ConglomeratesFinance WHI Special Investments LLC operates as a pooled investment fund. The company is headquartered in Chicago, IL. | Directeur/Membre du Conseil | - |
Bolden Therapeutics, Inc.
 Bolden Therapeutics, Inc. BiotechnologyHealth Technology Bolden Therapeutics, Inc. is a biotechnology company that is developing first-in-class therapeutics to treat central nervous system diseases. The company's research facilities are based within Tufts Launchpad Biolabs, a leading incubator for next-generation powerhouse biotech startups located in Providence, RI. The company's scientific co-founders, Dr. Justin Fallon and Dr. Ashley E. Webb, have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons in the adult brain. Bolden is developing antisense oligonucleotides to modulate this genetically-validated target. The company was founded by Justin Fallon, Ashley E. Webb, and Johnny Page. Johnny Page has been the CEO since incorporation. | Président | - |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Directeur/Membre du Conseil | - |
Anciens postes connus de Charles Polsky
| Sociétés | Poste | Fin |
|---|---|---|
RIGImmune, Inc.
 RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Directeur/Membre du Conseil | - |
Tivorsan Pharmaceuticals, Inc.
 Tivorsan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tivorsan Pharmaceuticals, Inc. is a protein therapeutics firm. It develops products to treat Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). The company was founded by Justin Fallon and Joel Bennett Braunstein and is headquartered in Providence, RI. | Directeur/Membre du Conseil | - |
Formation de Charles Polsky
| The University of Chicago | Doctorate Degree |
| Yale University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
William Harris Investors, Inc.
William Harris Investors, Inc. Investment ManagersFinance William Harris Investors, Inc. (WHI) is a privately-owned investment and wealth management firm headquartered in Chicago, Illinois. The firm serves as the family office for the Irving B. Harris family. Founded in 1976 by Irving B. Harris to manage his own family's capital, WHI has expanded its services and today provides a broad range of professional and wealth management services, including financial and estate planning, trust services, cash management, accounting and administrative services, tax preparation, and a variety of philanthropic services to four generations of the Harris family. | Finance |
Gliknik, Inc.
Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
WHI Special Investments LLC
WHI Special Investments LLC Financial ConglomeratesFinance WHI Special Investments LLC operates as a pooled investment fund. The company is headquartered in Chicago, IL. | Finance |
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Commercial Services |
Bolden Therapeutics, Inc.
Bolden Therapeutics, Inc. BiotechnologyHealth Technology Bolden Therapeutics, Inc. is a biotechnology company that is developing first-in-class therapeutics to treat central nervous system diseases. The company's research facilities are based within Tufts Launchpad Biolabs, a leading incubator for next-generation powerhouse biotech startups located in Providence, RI. The company's scientific co-founders, Dr. Justin Fallon and Dr. Ashley E. Webb, have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons in the adult brain. Bolden is developing antisense oligonucleotides to modulate this genetically-validated target. The company was founded by Justin Fallon, Ashley E. Webb, and Johnny Page. Johnny Page has been the CEO since incorporation. | Health Technology |
Tivorsan Pharmaceuticals, Inc.
Tivorsan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tivorsan Pharmaceuticals, Inc. is a protein therapeutics firm. It develops products to treat Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). The company was founded by Justin Fallon and Joel Bennett Braunstein and is headquartered in Providence, RI. | Health Technology |
